Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to a report in Chinese state media.
The researchers were dismissed and barred from government science projects for five years, China Central Television (CCTV) reported Nov. 13. Authorities took the actions after finding that the researchers failed to promptly report a preclinical safety signal, emphasized the risk of death in the informed consent form or disclosed the death in a journal paper, according to CCTV. The probe also found fault with the ethics review process.
Other findings included undisclosed conflicts of interest. Families gave the researchers money and gifts totaling about 1.1 million Chinese yuan ($160,000). The gifts, which were not disclosed in the research paper, included high-end liquor and electronic products, CCTV reported.
The findings triggered the dismissal of the person in charge of preclinical research and a key member of their team. Five other people received punishments ranging from demotions to administrative warnings, according to CCTV.
Authorities outlined actions they are taking to improve practices. Multiple organizations must submit written self-examinations and take steps to rectify the failings identified in the investigation, CCTV said. Authorities plan to strengthen oversight of clinical trials involving new biomedical technologies, such as gene editing therapies, according to the article.
The actions come as China implements new rules on investigator-initiated trials (IITs), which have enabled drug candidates to move quickly into early clinical development but raised questions about the adequacy of oversight and safety reporting. The revised rules limit which sites can run IITs and impose additional requirements on the studies.
Source: fiercebiotech.com
Under the deal, which is tied to up to $2.3 billion in milestone payments plus royalties, Pfizer will take the lead on the programs’ clinical development outside Greater China—although the pharma has the option to also bag the China rights at a later date.
CEO Christophe Bourdon said that an IPO remains a “natural and viable option” for the Danish drugmaker, but that the company’s shareholders have opted to delay that strategy out past this year, due to volatility in the global markets, Bloomberg first reported following an interview with the chief executive.
Amsterdam-based argenx partnered with UNP in 2025. Through that deal, which is worth up to $1.5 billion in biobucks, UNP used its macrocyclic peptide delivery platform to generate candidates against undruggable targets chosen by argenx.